Business Wire

ees Europe: The Rise of Large-Scale Storage Systems – Driving Growth in the Storage Market and an Indispensable Pillar of the Energy Transition

27.3.2025 15:52:00 CET | Business Wire | Press release

Share

The energy transition has reached a crucial point. With increasing electricity generation from renewable sources, the need for effective grid stabilization solutions is growing. Large-scale battery storage systems play a key role. According to SolarPower Europe, the European market will grow by 30–40% annually, driven by the rise of large-scale storage. These systems will be central to discussions at ees Europe, the continent’s largest trade fair for batteries and energy storage, from 7 to 9 May 2025.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250327880309/en/

Falling installation and operating costs as well as lower prices for batteries are boosting the large-scale storage boom. © Eco Stor GmbH

Germany is experiencing rapid growth in large-scale battery storage. In early 2023, 1.4 GWh were installed, with projections of 61 GWh by 2027 and 136 GWh by 2045. A Fraunhofer study predicts 104 GWh by 2030 and 178 GWh by 2040. By the end of 2024/25, 650 battery storage inquiries totaling 226 GW had been received.

Price erosion and fast amortization

Two key factors drive the large-scale storage boom: declining installation and operating costs, mainly due to falling battery prices, and attractive revenue opportunities in balancing energy and electricity trading. Leonhard Probst from Fraunhofer ISE estimates a three-year amortization period. Given a 15-year battery lifespan, this allows 12 years of profit generation.

Industry association calls for regulatory reform

SolarPower Europe expects longer-duration storage systems (4 to 8 hours) to become standard in Europe. However, hurdles such as technical standards and storage restrictions must be addressed, according to Dries Acke, Vice President of SolarPower Europe.

Integration and flexibility

Large-scale storage systems efficiently integrate increasing renewable electricity into the grid, ensuring power availability when needed. These systems support both grid stability and overall system efficiency. For Germany, Frontier Economics estimates that by 2050, day-ahead trading alone could yield at least €12 billion in economic benefits, mainly from fuel savings and CO2 reduction.

Grid boosters ease the burden on the power grid

Grid boosters—specialized battery storage systems—help alleviate grid bottlenecks. Tennet is operating two projects where one facility absorbs excess wind power in the north while the other feeds power into the grid in the south. This approach offers a cost-effective alternative to building new power lines.

ees Forum and ees Europe Conference: Large-scale storage systems under the spotlight

At ees Forum (Hall C2, Stand C2.230) on the first day of the trade fair, visitors can attend a session on business models and applications for large-scale storage. The ees Europe Conference, running on 6 and 7 May 2025 at the International Congress Center Messe München, will focus on regulatory requirements, investor preferences, project development, market trends, and the business outlook for large-scale storage systems. Large-scale battery storage is becoming a key component of the energy transition, enabling renewable integration, grid stability, and economic benefits. With technological advancements, declining costs, and growing demand, energy storage is set to play an increasingly vital role in Europe's renewable energy landscape.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250327880309/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye